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Abstract The purpose of this study was to identify the
clinical, [18F]-fluorodeoxyglucose positron emission to-
mography (FDG-PET) and amyloid-PET findings in a large
cohort of posterior cortical atrophy (PCA) patients, to ex-
amine the neural correlates of the classic features of PCA,
and to better understand the features associated with early
PCA. We prospectively recruited 25 patients who pre-
sented to the Mayo Clinic between March 2013 and August
2014 and met diagnostic criteria for PCA. All patients
underwent a standardized set of tests and amyloid imaging
with [11C] Pittsburg compound B (PiB). Seventeen (68 %)
underwent FDG-PET scanning. We divided the cohort at
the median disease duration of 4 years in order to assess
clinical and FDG-PET correlates of early PCA (n = 13).
The most common clinical features were simultanagnosia
(92 %), dysgraphia (68 %), poly-mini-myoclonus (64 %)
and oculomotor apraxia (56.5 %). On FDG-PET, hy-
pometabolism was observed bilaterally in the lateral and
medial parietal and occipital lobes. Simultanagnosia was
associated with hypometabolism in the right occipital lobe
and posterior cingulum, optic ataxia with hypometabolism
in left occipital lobe, and oculomotor apraxia with hy-
pometabolism in the left parietal lobe and posterior
cingulate gyrus. All 25 PCA patients were amyloid posi-
tive. Simultanagnosia was the only feature present in 85 %
of early PCA patients. The syndrome of PCA is associated
with posterior hemisphere hypometabolism and with
amyloid deposition. Many of the classic features of PCA
show associated focal, but not widespread, areas of in-
volvement of these posterior hemispheric regions. Simul-
tanagnosia appears to be the most common and hence
sensitive feature of early PCA.
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Introduction
Posterior cortical atrophy (PCA) is a neurodegenerative
disorder in which the onset of dementia is characterized by
the development of higher order visual deficits [1]. This
disease is often accompanied by visuospatial and visuop-
erceptual impairments, alexia, features of Ba´lint’s syn-
drome, Gerstmann’s syndrome and transcortical sensory
aphasia, whereas episodic memory is relatively preserved
or only mildly impaired [2]. These clinical features differ
from those of typical dementia of the Alzheimer’s type
(DAT) as they show preservation of memory, insight, and
judgment until late in the clinical course, when the clinical
features of PCA and DAT overlap [3]. The most frequent
pathological findings in PCA are tau neurofibrillary tangles
and beta-amyloid neuritic plaques which are characteristic
of Alzheimer’s disease [4], although other pathologies
have been described in PCA including corticobasal de-
generation, diffuse Lewy body disease, and Creutzfeldt-
Jakob disease [5–7]; frontotemporal dementia with pro-
granulin mutation has also been reported [8].
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The use of functional neuroimaging, using [18F]-
fluorodeoxyglucose positron emission tomography (FDG-
PET) allows the in vivo assessment of brain metabolism.
Previous FDG-PET studies in PCA patients have shown
prominent hypometabolism in the occipito-parietal region
with variable involvement of the frontal eye fields and the
relative sparing of the frontal and medial temporal cortex
[9–12]. However, in the majority of such studies there is no
information on pathology underlying PCA or information
on features occurring early in the disease course. Identi-
fying information about underlying pathology is important
since different pathologies could have different clinical
associations and hence confound the findings in any such
study. Additionally, understanding early PCA could have
an impact on prognosis and treatment.
In this study, we assessed for the presence of beta-
amyloid deposition on Pittsburgh compound B-PET (PiB-
PET) scanning in a large cohort of PCA patients and
assessed for clinical and FDG-PET findings. Additionally,
we assessed for the anatomic correlates of the classic fea-




We prospectively recruited all consecutive patients who
presented to the Department of Neurology, Mayo Clinic,
Rochester, Minnesota, between March 1st, 2013 and Au-
gust 31st, 2014 with a clinical diagnosis of PCA who also
fulfilled our research criteria for PCA (see below).
Posterior cortical atrophy was defined according to the
core criteria previously suggested [4, 13] as follows: (1)
insidious onset and gradual progression, (2) presentation of
visual complaints in the absence of significant primary
ocular disease explaining the symptoms, (3) relative
preservation of anterograde memory and insight early in
the disorder, (4) disabling visual impairment throughout
the disorder, and (5) presence of any of the following:
simultanagnosia with or without optic ataxia or oculomotor
apraxia, constructional dyspraxia, visual field defect, en-
vironmental disorientation or any elements of Gerstmann’s
syndrome (acalculia, agraphia, left–right disorientation and
finger agnosia).
Patients were included in this study if they also met the
following five research criterion for PCA. (1) The chief
complaint must be a progressive visuospatial or perceptual
problem. (2) The subject must have a normal ophthalmo-
logic examination within 3 months of presentation. (3)
Visuospatial/perceptual deficits must be corroborated on
neuropsychological testing of spatial/perceptual function.
(4) Performance on testing of episodic memory (the Rey
Auditory Verbal Learning Test was used for this study)
[14] must be superior to ([1.0 Z score) performance on
testing of visuospatial/perceptual function (the Rey-Oster-
rieth complex figure test was used) [15]. (5) The neu-
ropsychological test battery must demonstrate that
visuospatial/perceptual deficits are more severe than defi-
cits in all other cognitive domains. Patients with symptoms
suggestive of severe depression, an infarct or tumor in the
occipital, parietal or temporal lobes on head MRI/CT that
could have contributed to the presenting syndrome or with
medical conditions that could interfere with cognitive
performance were excluded.
Neurological assessments
All neurological assessments were performed by a behav-
ioral neurologist (KAJ). Demographic variables collected
included age, sex, education, handedness, race and disease
duration. All patients underwent testing with the Mini-
Mental State Examination (MMSE) [16], the Frontal
Assessment Battery (FAB) [17], Frontal Behavior Inven-
tory (FBI) [18], apraxia subset of the Western Aphasia
Battery (WAB-apraxia) [19], 15-item Boston Naming test
(BNT) [20], Movement Disorder Society-sponsored ver-
sion of the Unified Parkinson’s Disease Rating Scale (parts
I, II and III) (MDS-UPDRS) [21], Clinical Dementia Rat-
ing (CDR) [22], Neuropsychiatric Inventory (NPI) [23],
and a test of famous faces’ recognition [24]. Calculation
ability was assessed using the calculation subscore from
the Montreal Cognitive Assessment Battery [25]. In addi-
tion, the presence/absence of visual hallucinations, rapid
eye movement sleep behavior disorder (RBD) and poly-
mini-myoclonus at the time of testing were recorded. Rapid
eye movement sleep behavior disorder was considered
present if the behavior met diagnostic criteria B for rapid
eye movement sleep behavior disorder, defined as abnor-
mal, wild flailing movements occurring during sleep (with
sleep-related injuries) or movements that are potentially
injurious or disruptive [26]. Two of the four patients with
RBD had a polysomnography. One showed REM sleep
without atonia consistent with RBD. The other had REM
sleep with atonia but no non-supine REM sleep was cap-
tured. The presence of anomia was assessed using a cut-off
of\12 on the BNT. The presence of simultanagnosia was
assessed using the Ishihara color plates and the documen-
tation of how many items were recognized on visual in-
spection of a picture with five overlapping items. Cutoff
was below 6/6 for plates and below 5/5 on overlapping
pictures based on performance of 10 normal controls that
scored 100 % on both tests. Handwriting samples were
assessed for evidence of dysgraphia (Fig. 1). The presence/
absence of oculomotor apraxia and optic ataxia were
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assessed on neurological examination. Oculomotor apraxia
was defined as the inability to voluntarily direct one’s gaze
to a particular point. Optic ataxia was defined as the im-
pairment of goal-directed hand movements towards visually
presented targets. Poly-mini-myoclonus was defined as the
presence of intermittent and irregular jerks that are visible
predominantly in the fingers when the arm is held out-
stretched and the figures extended, with amplitudes of the
jerks just sufficient to produce movements of the joints [27].
Image acquisition
All patients underwent PiB-PET scanning, while 17 (68 %)
underwent FDG-PET, with both acquired using a PET/CT
scanner (GE Healthcare, Milwaukee, Wisconsin) as pre-
viously described. PET images were acquired after injec-
tion of C-11 PiB (average = 596 MBq; range =
292–729 MBq, uptake period = 40 min) and F-18-FDG
(average = 540 MBq; range = 366–399 MBq, uptake pe-
riod = 30 min); both scans were performed as previously
described on the same day with 1 h interval between ac-
quisitions [24]. All patients also underwent a standardized
MRI imaging protocol at 3.0 T, which included a 3D
magnetization prepared rapid acquisition gradient echo
(MPRAGE) sequence [24]. A global PiB standardized
uptake value ratio (SUVR) was calculated for each PiB-
PET scan as previously described [28], with a 1.5 cut-off
used for beta-amyloid positivity.
PET analyses
The FDG-PET images were analyzed both at the individual
and group-level. Individual maps of hypometabolism were
generated using 3-dimensional stereotactic surface projec-
tions. The software package used to perform these analyses
was CortexID (GE Healthcare, Waukesha, WI, USA).
Automated average Z scores generated from Cortex ID
were calculated for the following regions: lateral and me-
dial frontal lobes, lateral and medial parietal lobes, tem-
poral lobes, cingulate cortex, occipital lobe, and primary
visual cortex. Hypometabolism was considered present if
Z scores were greater than 2. Additionally, Z scores of 2–3
were considered moderate hypometabolism and[3 were
considered severe hypometabolism.
Group-level analyses were performed using SPM5 [29].
The FDG-PET scan for each subject was co-registered to
the subjects MPRAGE scan using 6 degrees-of-freedom
registration. The automated anatomical labelling atlas [30]
containing pons was propagated to native MPRAGE space.
All voxels in the FDG-PET image were then divided by
median uptake of the pons to form FDG uptake ratio im-
ages. The MPRAGE scans were then normalized to a
customized template, and these normalization parameters
were used to also transform the FDG-PET uptake ratio
images onto the customized template. Voxel-level com-
parisons of FDG-PET were performed using two-sided
t tests in SPM5. The group of PCA subjects was compared
to an age and gender-matched group of 20 healthy controls
that had undergone identical FDG-PET and MRI acquisi-
tions. These comparisons were performed after correction
for multiple comparisons using the false discovery rate
(FDR) correction at p\ 0.001.
Group-level analyses of the PiB-PET scans were also
performed using SPM5. As above, the PiB-PET scans were
co-registered to the subjects MPRAGE and transformed
into customized template space using the normalization
parameters from the MPRAGE normalization. All voxels
in the PiB-PET images were divided by median uptake in
the cerebellum before normalization. Two-sided t tests
were used to compare the PCA subjects to the 20 healthy
controls. These comparisons were performed after correc-
tion for multiple comparisons using the false discovery rate
(FDR) correction at p\ 0.001.
Early PCA
We subdivided the 25 PCA patients based on the median
disease duration of the cohort (4 years) in order to assess
clinical and FDG-PET features of those that had a short
duration of B4 years (n = 13) and hence could be con-
sidered to have early PCA. Disease duration was defined as
the time from the onset of the first symptom observed by
the patient and the patient’s significant other (both had to
agree) to the time of presentation. Ten early PCA patients
had an FDG-PET scan performed B4 years after onset,
available for analysis. Patterns of FDG-PET hy-
pometabolism were compared between the group of early
PCA patients and the 20 controls correcting for multiple
comparisons using the FDR correction at p\ 0.001 and
Fig. 1 Examples of handwriting from three PCA patients. Note
abnormally formed letters, abnormal spacing, and variations in letter
size, consistent with apraxic dysgraphia
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between early PCA and the rest of the PCA cohort at
p\ 0.001 uncorrected.
Statistical analysis
We used JMP software version 10.0.0 (SAS Institute Inc.,
Cary, NC, USA) to perform statistical analyses. According
to convention, statistical significance is represented at two-
tailed alpha level of 0.05. Group differences for categorical
variables were assessed with the v2 test and Fisher’s exact
test as appropriate, while differences in continuous vari-
ables were assessed using the Kruskal–Wallis test. Spear-
man Correlation analyses were performed between
neuropsychological and clinical symptoms and hy-
pometabolism Z scores.
Results
We identified 25 PCA patients who fulfilled our research
criteria for PCA. Two patients were excluded because they
presented with aphasia rather than visuoperceptual deficits.
The demographic features of all 25 patients are shown in
Table 1.
Clinical findings
The clinical features of the cohort are shown in Table 2.
The most common clinical features in the cohort were si-
multanagnosia, dysgraphia (Fig. 1), poly-mini-myoclonus
and oculomotor apraxia. On neurological testing all scores
fell within the normal- mildly affected range except for
Ishihara plates in which the average score fell within the
severely affected range.
Single subject FDG-PET analysis
The Z scores for hypometabolism and the number of af-
fected patients are shown in Table 3. Severe hy-
pometabolism was seen in the right parietal lobe in 16
(94.1 %) patients, left parietal lobe in 14 (82.4 %)
extending through the right and left medial parietal lobes in
16 (94.1 %) and 14 (82.4 %) patients and finally involving
the right and left occipital lobes in 14 (82.4 %) and 15
(88.2 %) patients. Mild hypometabolism was present in
bilateral frontal and temporal lobes, extending through the
left and right posterior cingulum, and the bilateral visual
cortex. Both medial frontal cortices and anterior cingulum
remained unaffected in all the patients of our cohort.
Group analysis of FDG-PET using SPM
The regions of hypometabolism observed in all 17 patients
are shown in Fig. 2. There was reduced metabolism bilat-
erally throughout lateral parietal and occipital cortices,
precuneus and posterior cingulate, lateral posterior tem-
poral cortex and medial occipital cortex, particularly in the
right hemisphere, compared to controls.
Associations between classic PCA clinical features
and FDG-PET
Simultanagnosia was associated with hypometabolism in
the right occipital lobe (p = 0.0054), right posterior cin-
gulum (p = 0.0186) and the right visual cortex
(p = 0.0193). In contrast, optic ataxia was associated with
hypometabolism in left occipital lobe (p = 0.0109) and left
visual cortex (p = 0.0339) and oculomotor apraxia with
left parietal lobe (p = 0.0357), left posterior cingulate
gyrus (p = 0.0157) and left medial parietal cortex
(p = 0.0175). There was no association between dys-
graphia and acalculia and the hypometabolism patterns.
Early PCA
Demographic features were similar between early PCA
and all PCA patients (Table 1). Only four features were
present in more than 50 % of the early PCA patients
including simultanagnosia, dysgraphia, poly-mini-my-
oclonus and oculomotor apraxia (Table 2). Only simul-
tanagnosia was present in 85 % of the early PCA patients.
The only feature than differed by more than 20 %
Table 1 Demographic features
of the PCA cohort
Demographics Entire PCA cohort (n = 25) Early PCA (n = 13)
Males 12 (48 %) 7 (53.9 %)
Right handedness 24 (96 %) 12 (92.3 %)
Age of onset (years) 60 (54–63) 59 (54–62.5)
Age at evaluation (years) 64 (58–70) 61 (56.5–65.5)
Illness duration (years) 4 (3–7) 3 (2.5–4)
Education 16 (13–18) 14 (12–16)
Race (Caucasian) 25 (100 %) 13 (100 %)
Data expressed as n (%) or median (IQR)
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Table 2 Clinical and
neurological features of the
PCA cohort
Entire PCA cohort (n = 25) Early PCA (n = 13)
Clinical features (present/absent)
Simultanagnosia 23 (92 %) 11 (85 %)
Dysgraphia 17 (68 %) 9 (69.2 %)
Poly-mini-myoclonus 16 (64 %) 9 (69.2 %)
Oculomotor apraxia 13 (56.5 %) 6 (54.6 %)
Anomia 8 (34.8 %) 3 (23.1 %)
Optic ataxia 8 (34.8 %) 0 (0 %)
Visual hallucinations 5 (20 %) 3 (23.1 %)
REM sleep behavior disorder 4 (16 %) 3 (23.1 %)
Neurological test scores
MMSE (/30) 25 (20–28) 26 (24–29)
FAB (/18) 14 (11–16) 15 (12–15.5)
FBI (/72) 12 (8–18.5) 11 (5.5–17.5)
WAB apraxia (/60) 55 (52–59) 56 (53–58.5)
MDS-UPDRS I (/52) 7 (5.5–10.5) 7 (5.5–9.5)
MDS-UPDRS II (/52) 6 (1.5–1.3) 4 (1–7)
MDS-UPDRS III (/132) 2 (0.5–4) 2 (0.5–3)
CDR sum of boxes (/18) 3.5 (2–6.8) 2.5 (1.8–4)
NPI total score (/36) 4 (2–6) 4 (2.5–5.5)
Boston naming test (/15) 13 (10–14) 13 (11–15)
Famous face recognition (/10) 9 (7–10) 10 (9–10)
Calculations (/5) 2 (0–3) 2 (0.5–3)
Ishihara (6 plates) 0 (0–2) 1.5 (0–3)
Data as (%) or median (IQR)
Table 3 Z scores of
hypometabolic patterns in PCA
Z scores (median) No (%) patients with Z score[2
Parietal lobe, R 4.26 16 (94.1)
Parietal lobe, L 3.75 14 (82.4)
Medial parietal, R 3.36 16 (94.1)
Occipital lobe, R 3.18 14 (82.4)
Occipital lobe, L 2.97 15 (88.2)
Medial parietal, L 2.86 14 (82.4)
Temporal lobe, L 2.61 11 (64.7)
Temporal lobe, R 2.48 13 (76.5)
Posterior cingulate, L 1.87 6 (35.3)
Posterior cingulate, R 1.80 8 (47.1)
Frontal lobe, L 1.79 6 (35.3)
Visual cortex, R 1.64 6 (35.3)
Visual cortex, L 1.49 5 (29.4)
Frontal lobe, R 1.38 6 (35.3)
Medial frontal, L 1.16 0 (0)
Anterior cingulate, R 0.98 0 (0)
Medial frontal, R 0.97 0 (0)
Anterior cingulate, L 0.76 0 (0)
Values are ordered from most affected to least affected. Bold and italicized values represent degree of
severity ([3.00 = severe, 2.00–3.00 = moderate, 1–1.99 = mild)
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between early PCA and the entire cohort was optic ataxia.
Three patients had disease duration of less than 2 years of
which two had simultanagnosia and poly-mini-myoclonus.
Performance on neurological testing in early PCA was
similar to performance in the entire PCA cohort although
the early PCA patients were in general less cognitively
impaired.
In the SPM analysis (Fig. 2), the early PCA group
showed a similar pattern of hypometabolism to the entire
cohort although there was less involvement of the occipital
cortex in early PCA compared to the rest of the cohort.
PiB-PET analysis
All 25 PCA patients had an SUVR ratio[1.50 and hence
were amyloid positive. The average SUVR ratio for all 25
PCA patients was[2.19 (±0.35). Twenty of the 25 (90 %)
PCA patients had an SUVR[2.00. The regional pattern of
PiB-PET uptake is shown in Fig. 3. Widespread PiB-PET
uptake was observed with most severe uptake in lateral and
medial prefrontal, lateral temporal and medial parietal
cortex.
The average SUVR ratio of the early PCA patients was
2.08 (±0.31). Eleven of the 13 (87 %) early PCA patients
had an SUVR ratio [2.00. There was no difference in
SUVR ratio between early PCA and the rest of the PCA
cohort.
Discussion
This is one of the largest prospective studies to date of a
cohort of patients with a clinical diagnosis of PCA that
underwent FDG-PET and amyloid PET imaging. The study
identifies important clinical, cognitive and neuroimaging
features of PCA.
While the clinical features of our PCA patients are un-
surprisingly similar to previously reported PCA cohorts [2,
4, 13, 31–33], our study design allowed us to further refine
the clinical syndrome of PCA. Our PCA cohort had an
average age of onset of 60 years which might suggest that
PCA should be considered an early onset dementia. How-
ever, we did not have any subjects presenting less than
45 years and hence PCA would not be considered a young
onset dementia, based on our previous definitions [34].
Simultanagnosia was noted to be the most common clinical
feature in our cohort in general, and was also the most
common feature of early PCA, affecting 85 % of patients
with disease duration of 4 years or less. Dysgraphia and
oculomotor apraxia were also common features of PCA,
and of early PCA. Poly-mini-myoclonus however, is not a
feature that is considered, or typically assessed, in patients
with PCA yet it was more common than some of the fea-
tures typically associated with PCA, such as oculomotor
apraxia and optic ataxia. We previously reported an asso-
ciation between poly-mini-myoclonus and PCA [35],
although our previous study was retrospective in nature and
clearly underestimated the frequency of this clinical feature
compared to the current prospectively recruited cohort,
which shows that poly-mini-myoclonus is a common fea-
ture of PCA. In contrast to simultanagnosia, oculomotor
apraxia and poly-mini-myoclonus, our data suggested that
optic ataxia, while relatively common in PCA, is a later
feature of PCA. In fact, optic ataxia was not identified in
early PCA. Anomia was also observed in our PCA cohort,
as previously reported [4, 33, 35, 36], and is most likely
due to involvement of the left temporal lobe. We also
found that approximately 20 % of our cohort had visual
hallucinations or RBD, with the frequency similar in early
PCA and across the entire cohort. This suggests that hal-
lucinations and RBD when associated with PCA are both
likely to be observed early in the disease course. These two
Fig. 2 Three-dimensional brain renderings showing FDG-PET hy-
pometabolism in the entire PCA cohort compared to controls (a), the
early PCA subjects compared to controls (b), and early PCA
compared to the rest of the PCA patients (c). Renders were generated
using the BrainNet Viewer (http://www.nitrc.org/projects/bnv/)
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features are not frequently reported in PCA, but are sug-
gestive of underlying Lewy body disease [7, 35], given
these are classic features of dementia with Lewy bodies
[37]. Acalculia, a feature of the Gerstmann’s syndrome,
was striking and was also observed in early PCA.
Prosopagnosia was noted to be present in some of the pa-
tients but was relatively mild when present in most in-
stances and was most likely perceptual, as opposed to
agnostic in nature. Neuropsychiatric, behavioral, executive
and extrapyramidal features were noted to be absent to
mild in PCA. Ideomotor apraxia was not a common feature
and when present also appeared to be mild in most patients.
On FDG-PET analysis, we observed marked hy-
pometabolism of the bilateral parietal and occipital lobes,
showing involvement of these regions in more than 80 %
of the PCA patients. Mild hypometabolism in bilateral
frontal lobes, posterior cingulate and the bilateral visual
cortex was observed in 50 % of the PCA patients. The
bilateral anterior cingulate and medial frontal cortex ap-
pears to remain unaffected. These findings concur with
previous PET studies [9–12]. All 25 PCA patients were
amyloid positive with very high SUVR ratios. This suggest,
with high certainty that the underlying pathology in all of
our PCA patients is Alzheimer’s disease. It is also possible
however, although less likely, that in some of our cases
amyloid deposition is co-occurring with another pathology,
such as corticobasal degeneration that has been reported in
a couple of PCA patients [6]. It is also unlikely that our
patients suffered from Creutzfeldt-Jakob disease, given the
disease durations and the fact that amyloid imaging is
negative in Creutzfeldt-Jakob disease [38]. Furthermore,
large amplitude myoclonic jerks, a feature of Creutzfeldt-
Jakob disease, was not observed in our cohort. Our PCA
patients instead showed poly-mini-myoclonus. Therefore,
our cohort is likely very homogeneous, pathologically,
although it is possible that in some patients there is co-
existing Lewy body pathology.
Our association analyses allowed us to investigate the
hypometabolic associations of the clinical features ob-
served in PCA. Simultanagnosia was associated with hy-
pometabolism in the right occipital lobe, posterior
cingulum and visual cortex. These findings are expected as
simultanagnosia generally reflects the severity of damage
in the visual associative cortex without the involvement of
the lateral parietal cortex [2, 39]. However, in our study it
was found to be associated only with right-sided involve-
ment. Optic ataxia was associated with involvement of the
left occipital and visual cortex, while oculomotor apraxia
with left parietal lobe and posterior cingulum. These results
further quantify the neural correlations of oculomotor
apraxia to the posterior parietal cortices. In fact, an fMRI
study recently reported finding an association between the
lateral occipitoparietal junction (dorsal stream) and chan-
ges in graspable stimuli and visually guided reaching to
grasp [40, 41]. The optic ataxia findings suggest that oc-
cipital lobe involvement needs to be present before this
PCA feature will emerge. We did not find any association
between two of the features of Gerstmann’s syndrome
(acalculia and agraphia) with any hypometabolic patterns,
which could be due a small sample size of our cohort;
Fig. 3 Three-dimensional brain
renderings showing PiB-PET
uptake in the entire PCA cohort
compared to controls. Renders
were generated using the
BrainNet Viewer (http://www.
nitrc.org/projects/bnv/)
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however, these findings have been shown to be associated
with the left parietal cortex by another group [42].
One of the important aspects of our study was the
assessment of clinical and FDG-PET features of early
PCA. We observed little difference in early PCA compared
to the entire cohort suggesting most features of PCA will
be present early in the disease course. The only exception
appeared to be optic ataxia which was not a feature of early
PCA. Interestingly, the presence of optic ataxia was asso-
ciated with left occipital lobe involvement which was a
region found to be less affected in early PCA. And
although we do not have longitudinal data, we can spec-
ulate that progressive involvement likely spreads from the
right parietal lobe across to the left occipital lobe, which
would explain the later emergence of optic ataxia.
All 25 PCA patients had SUVR ratios consistent with
beta-amyloid deposition. Beta-amyloid is one of the two
major proteins required for a pathological diagnosis of
Alzheimer’s disease; tau being the other. Our group analysis
of PiB did not show a regional pattern of beta-amyloid
deposition unique to PCA. Prefrontal, temporal and medial
parietal involvement has also been observed with other
Alzheimer’s disease related syndromes [28, 43, 44]. The
lack of beta-amyloid deposition being more striking in the
occipitoparietal regions, mirroring the pattern of hy-
pometabolism on FDG-PET, is consistent with pathological
studies demonstrating greater tau, but not beta-amyloid
deposition in these regions [4]. The subjects in this study all
met clinical criteria for PCA [4, 13]. All subjects also met
stringent research criteria for PCA. Given that we did not
have any amyloid negative subjects in our cohort, it appears
that our research criteria may be more specific to underlying
Alzheimer’s disease than the clinical criteria, since other
PCA cohorts have found subjects with non-Alzheimer’s
pathologies [5, 6]. We have previously reported two sub-
jects who presented with aphasia but were agnostic to their
visual deficits [45]. Visuospatial/perceptual deficits were
strikingly abnormal on neuropsychological testings and was
the most severely impairment cognitive domain in both.
Such subjects remain controversial in terms of classifica-
tion. In fact, both were excluded from this study as they did
not meet our research criteria for PCA.
The major strength of this study is the large number of
PCA cases that were prospectively recruited and underwent
amyloid and FDG-PET imaging. Another strength was the
assessment of PCA subjects with short disease duration
allowing the assessment of early features of PCA. A
limitation of the study was that not all subjects underwent
FDG-PET. In addition, pathological confirmation of Alz-
heimer’s disease was not available. The lack of autopsy
also meant we could not confirm an association between
the presence of hallucinations and RBD and co-existence
of Lewy body disease.
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